Anette Sundstedt
Director/Board Member bij ALLIGATOR BIOSCIENCE AB
Profiel
Anette Sundstedt is currently the Director at Alligator Bioscience AB.
Previously, she worked as the Director at Active Biotech AB from 2001 to 2016.
She also served as the Chief Scientific Officer at Idogen AB.
Additionally, she held the position of Chief Development Officer at CanImGuide Therapeutics AB from 2020 to 2021.
Dr. Sundstedt obtained her graduate and doctorate degrees from the University of Lund.
Actieve functies van Anette Sundstedt
| Bedrijven | Functie | Begin |
|---|---|---|
| ALLIGATOR BIOSCIENCE AB | Director/Board Member | 05-07-2023 |
Eerdere bekende functies van Anette Sundstedt
| Bedrijven | Functie | Einde |
|---|---|---|
CanImGuide Therapeutics AB
 CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Corporate Officer/Principal | 01-03-2021 |
| ACTIVE BIOTECH AB | Director/Board Member | 01-01-2016 |
| IDOGEN AB (PUBL) | Chief Tech/Sci/R&D Officer | - |
Opleiding van Anette Sundstedt
| University of Lund | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ACTIVE BIOTECH AB | Health Technology |
| ALLIGATOR BIOSCIENCE AB | Health Technology |
| IDOGEN AB (PUBL) | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Health Technology |
